Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAH
Strong BuyFLAGCardinal Health, Inc. · Healthcare · United States · $54.6B · Avg Vol: $440M/d
Cardinal Health has quality Q64 and momentum M68, but value at V49 is one point below the calibrated floor, so stage one fails, consistent with the Mexican line flagged earlier in this run.
COMPANY DESCRIPTION
Cardinal Health, Inc. is a global integrated healthcare services and products company, playing a critical role in the healthcare supply chain through pharmaceutical and medical products distribution. The company's immense scale and extensive logistical network provide an indispensable link between manufacturers and healthcare providers, ensuring efficient delivery of essential supplies. This market position, alongside its portfolio of medical products, creates a significant competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 181.3B | 205.0B | 226.8B | 222.6B | 7.1% | 254.2B | 232.6B | 246.7B | 3.5% |
| EPS | -3.35 | 1.00 | 3.48 | 6.48 | 154.6% | 7.23 | 9.17 | 9.48 | 13.5% |
| Shares | 273.0M | 251.0M | 244.0M | 238.7M | -12.6% | 232.6M | — | — | — |
| Debt | 5.3B | 4.7B | 5.1B | 8.5B | 17.1% | 10.0B | — | — | — |
| Equity | -709.0M | -3.0B | -3.2B | -2.8B | — | — | — | — | — |
| Op CF | 3.2B | 2.8B | 3.8B | 2.4B | -8.9% | 5.2B | — | — | — |
| Inv CF | 567.0M | -454.0M | -1.8B | -5.6B | — | — | — | — | — |
| Fin CF | -2.5B | -3.1B | -847.0M | 1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAH | Cardinal Health, Inc.(you) | $54.6B | 91 | Strong Buy |
| COR | Cencora, Inc. | $61.5B | 65 | Hold |
| MCK | McKesson Corporation | $104.2B | 75 | Buy |
| HSIC | Henry Schein, Inc. | $10.0B | 84 | Strong Buy |
| 601607.SS | Shanghai Pharmaceuticals Holding Co., Ltd | $9.0B | 83 | Strong Buy |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 88 | Strong Buy |
| 7459.T | MediPal Holdings Corporation | $3.7B | 94 | Strong Buy |
| SIG.AX | Sigma Healthcare Limited | $22.1B | 51 | Hold |
| 600511.SS | China National Medicines Corporation Ltd. | $3.0B | 92 | Strong Buy |
| 2784.T | Alfresa Holdings Corporation | $2.5B | 84 | Strong Buy |
Peer medians: ROE 2.0% · P/E 24.0x · Gross margin 52.2%